Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

• Main Authors: M. Schwarz (Author), C. Schwarz (Author), A. Schütz (Author), C. Schwanke (Author), E. Krabb (Author), R. Schubert (Author), S.-T. Liebich (Author), D. Bauer (Author), L. Burghart (Author), L. Brinkmann (Author), E. Gutic (Author), T. Reiberger (Author), H. Haltmayer (Author), M. Gschwantler (Author)
• Format: Book
• Published: Elsevier, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background & aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this issue, we have combined ong...